What changed for Pancreatitis
A plain English summary of what recently moved in the public data Voxsanity tracks for Pancreatitis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 139 to 143 (+4)
- Trials on record 808 to 816 (+8)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Pancreatitis yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 44 trials tracked for Pancreatitis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03707431 · results posted 9 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 90 young people with abdominal pain — 44 in a web-based pain education programme (called WebED) and 46 in a web-based cognitive behavioural therapy programme (called WebMAP, a structured online talking therapy). The trial measured how each programme related to changes in pain severity, daily functioning, quality of life, emotional wellbeing, pain self-confidence, and medication use, across three time points: the start of the study, straight after the programme ended, and six months later. The reported data shows that...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05664074 · results posted 12 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 192 people in total — 96 in each group. All 192 participants completed the study. The trial was comparing two pain-relieving medications given around the time of a procedure called ERCP (a scope procedure used to examine the bile and pancreatic ducts): one group received rectal indomethacin (a suppository) and the other received IV ketorolac (given through a drip). The main thing the trial was measuring was whether participants developed a complication called post-ERCP pancreatitis — an inflammation of the pancreas th...
-
NCT03609944 · results posted 30 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03609944) enrolled 148 people in total — 73 in one group and 75 in the other. Participants were randomly assigned to one of two procedures: an ultrasound-guided procedure called EUS combined with a sham (inactive) procedure, or EUS combined with a procedure called ERCP with minor endoscopic sphincterotomy (miES), which involves a small cut in a duct opening in the digestive system. The trial was measuring whether the second procedure could reduce the number of future episodes of acute pancreatitis (sudden, painful inflamma...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04232670 · results posted 24 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved 14 people in total — 6 in one group and 8 in another. The trial was looking at two different procedures for people with pancreatic pain: one group received an ultrasound-guided injection procedure (called EUS) combined with a sham (inactive) version of a second procedure, while the other group received the same ultrasound-guided injection combined with an active pancreatic procedure called endotherapy. The main thing being measured was how much participants' daily pain scores changed over 90 days, using a standard 0–1...
-
NCT06098729 · results posted 17 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06098729) involved 24 people who used a digital exercise application. Twenty-three of the 24 participants completed the study, with one person not finishing. The trial was measuring three main things: how much time participants spent using the app to exercise, how satisfied they were with it, and how accurately the app could predict when a person was likely to stop exercising for a period of time. It also looked at participants' motivation to be physically active, how many minutes of moderate to vigorous physical activity...
-
NCT05251233 · results posted 6 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05251233) enrolled 56 people in total across three groups: 21 in a placebo group, 20 receiving a proton pump inhibitor (a type of medication commonly used to reduce stomach acid), and 15 in an "unassigned" group. The trial was looking at outcomes following a type of stomach surgery, with the main focus being on a condition called delayed gastric emptying — where the stomach takes longer than normal to move food through — measured using two different grading systems. By the end of the study, 14 people in the placebo group a...
-
NCT04816877 · results posted 22 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04816877) enrolled a very small number of participants — 3 people in the Patient Controlled Analgesia (PCA) group, where patients manage their own pain relief doses, and 4 people in the Physician Directed Analgesia (PDA) group, where doctors decide when and how much pain relief is given. One person in the PCA group did not complete the study, while all four in the PDA group did. The trial was measuring things like how long people stayed in hospital, how long before they could eat again, their pain scores, and how much opio...
-
NCT04207060 · results posted 4 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04207060) enrolled 27 people in total — 13 in the indomethacin group and 14 in the placebo group. Indomethacin is an anti-inflammatory medicine, and the trial was looking at whether it influenced certain biological and symptom measures in people with a pancreas condition. The main thing being measured was the change in levels of a substance called Prostaglandin E2 (PGE2) — a chemical found in pancreatic fluid that is linked to inflammation — before and after the treatment period. A number of secondary measures were also tr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04863014 · results posted 22 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04863014) enrolled 21 participants in total — 10 received a placebo (an inactive substance) and 11 received the study drug, evinacumab. The trial ran for 52 weeks and was measuring changes in several blood fat and cholesterol markers, including triglycerides (a type of fat found in the blood), total cholesterol, and various proteins that help carry fats around the body (called apolipoproteins). Of the 21 people who started, 12 completed the study — 7 in the placebo group and 5 in the evinacumab group. The remaining 9 parti...
-
NCT05162014 · results posted 18 March 2024
According to the results reported on ClinicalTrials.gov, this trial looked at real-world health records from people who had been prescribed one of two types of diabetes medication — empagliflozin or sulfonylureas (an older class of diabetes tablet). The study started with 72,661 people in the empagliflozin group and 422,018 in the sulfonylurea group. To make the two groups as comparable as possible, a statistical matching process was applied, leaving 72,621 people in each group for the main analysis. The trial was measuring how often people developed acute pancreatitis (a sudden, serious infla...
-
NCT03452228 · results posted 16 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03452228) tested a medicine called evinacumab, given by drip into a vein (intravenous infusion) every four weeks, in people with very high levels of triglycerides (a type of fat) in the blood. The trial had two back-to-back stages: a 12-week "double-blind" stage (where neither participants nor researchers knew who received evinacumab or a dummy treatment called a placebo), followed by a 12-week "single-blind" stage (where researchers knew, but participants did not, that everyone received evinacumab). A total of 52 people s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01543256 · results posted 9 January 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 164 people in total — 80 in a group that received metal stents and 84 in a group that received plastic stents. Stents are small tubes placed inside a bile duct to hold it open. The trial was looking at whether a narrowing in the bile duct (called a stricture) could be resolved over a 24-month period, comparing these two types of stents. Of those who started, 62 in the metal stent group and 70 in the plastic stent group completed the study. The reported data shows that, for the main outcome — whether the bile duct str...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02797067 · results posted 26 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,370 people in total — 685 in each group. Participants were randomly assigned to receive either indomethacin (a type of anti-inflammatory medicine given as a suppository) or glycerin (a plain suppository used as a comparison) before or after a procedure called ESWL (extracorporeal shock wave lithotripsy), which uses sound waves to break up stones in the pancreas. The main thing the trial was measuring was how many people in each group developed pancreatitis (inflammation of the pancreas) after the procedure. The rep...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02743364 · results posted 4 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02743364) enrolled a total of 8 participants — 6 in the simvastatin group and 2 in the placebo group. All 8 participants completed the study. The trial was looking at whether simvastatin, a commonly used cholesterol-lowering medicine, had any measurable effect on the pancreas in people with chronic pancreatitis (long-term inflammation of the pancreas). The main thing being measured was a change in the pancreas's ability to produce bicarbonate (a fluid the pancreas normally releases to help digestion), tested using a camera...
-
NCT03401190 · results posted 7 December 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03401190) involved 21 people in total who had been diagnosed with acute pancreatitis (a sudden inflammation of the pancreas) along with signs of a body-wide inflammatory response or low oxygen levels. Participants were divided into three groups: a low-dose group (8 people), a high-dose group (6 people), and a standard care group (7 people). The trial was testing a medicine called CM4620-IE, given alongside standard care in the two treatment groups, and was primarily looking at how often, how long, and how seriously unwante...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02577640 · results posted 12 November 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 11 participants, who were divided into groups receiving increasing amounts of a soy bread intervention. Four people were in the first dose group, three in the second, three in the third, and one in a final "maximally tolerated dose" group. The trial was designed to test how well participants could tolerate different dose levels of the soy bread, and to look at changes in a blood marker linked to inflammation (called TNF-alpha, a type of protein the body produces as part of an immune response). The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02318134 · results posted 14 April 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people — 30 in a group that received faecal microbiota transplantation (FMT, a procedure where gut bacteria from a healthy donor are transferred to a patient) and 30 in a control group who did not receive FMT. Almost all participants completed the study (28 in the FMT group and 29 in the control group). The trial was looking at gut function recovery in people with a serious condition, using a scoring system called the Gastrointestinal Failure (GIF) score, where a score of zero means the gut is working well enough t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01441492 · results posted 31 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01441492) enrolled 399 people who had undergone surgery — 197 were assigned to a "no drains" group and 202 to a "drains" group. Of those, 170 and 174 respectively completed the study. The trial was measuring whether using surgical drains (tubes sometimes left in the body after an operation to remove fluid) made a difference to the rate and seriousness of complications in the 60 days following surgery. The reported data shows that for the main outcome — the number of patients who experienced at least one complication rated...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02869893 · results posted 7 August 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 57 healthy participants, with 50 completing the study and 7 not completing it. The trial was measuring how the pancreas responds to a substance called secretin — which normally triggers the pancreas to release fluid — using a type of MRI scan. The researchers were looking at things like how much fluid the pancreas produced, how stiff the pancreatic tissue appeared on imaging, and the overall size (volume) of the pancreas. These measurements in healthy people appear to have been gathered as a reference point. The repo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01424215 · results posted 12 May 2020
According to the results reported on ClinicalTrials.gov, this trial involved 100 people in total — 50 in each of two groups. One group had a procedure using an ICG (fluorescent dye) injection combined with a special imaging scope (called Spyscope), while the other group had a standard surgical technique called the "Critical View" approach. The trial was measuring how long gallbladder removal surgery took, and specifically how quickly the surgeon could identify the key structures during the operation. The reported data shows that, for the main measurement — the time from the start of dissectio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01014390 · results posted 19 February 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 187 participants, all of whom received a device called the WallFlex Biliary RX Fully Covered (FC) Stent System — a type of tube placed in the bile duct to help keep it open. Of the 187 people who started the trial, 177 completed it, and 10 did not complete it (the reasons were not detailed in the reported data). The trial was a single-group study, meaning everyone received the same device with no comparison group. The main thing the trial set out to measure was called "stent removability" — specifically, whether the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01967888 · results posted 9 October 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01967888) looked at a medicine called reparixin in people who had undergone a procedure called islet autotransplantation — where insulin-producing cells are taken from a person's own pancreas and transplanted back into them, usually after the pancreas is removed. A total of 52 people received reparixin and 52 received a placebo (a dummy treatment with no active ingredient). The main thing the trial was measuring was how many people in each group no longer needed insulin injections one year after the transplant, based on sp...
-
NCT03245619 · results posted 20 September 2019
According to the results reported on ClinicalTrials.gov, this trial tested a drug called GSK3335065 and was designed to run in three parts (Part A, Part B, and Part C). The trial was set up to look at a range of doses — some given as tablets and some given directly into a vein — and compared these against a placebo (a dummy treatment with no active ingredient). Based on the data submitted, only Part A appears to have enrolled participants: 5 people received placebo, 6 received the 0.1 mg dose, 6 received the 0.25 mg dose, and 1 received the 1.3 mg dose. The reported data shows that Parts B and...
-
NCT01912716 · results posted 18 June 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01912716) enrolled 1,037 people in total — 522 in the high-dose group and 515 in the standard-dose group. The trial was comparing two different doses of a medicine called indomethacin (200 mg versus 100 mg) to see whether either dose was associated with a difference in the number of people who developed a complication called post-ERCP pancreatitis — that is, pancreas inflammation occurring after a common bile duct procedure known as an ERCP. All 1,037 participants completed the study. The reported data shows that, for the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02849704 · results posted 3 May 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people with chronic pancreatitis (a long-term condition where the pancreas is inflamed and does not work properly) and 24 healthy volunteers, for a total of 48 participants. The trial was measuring how well the body absorbs fat and energy from food, comparing the two groups. It used three different methods to do this: a blood test that tracks a type of fat in the bloodstream over time (called HA AUC — essentially a score for how much fat is absorbed), a stool test that calculated what percentage of eaten fat was ac...
-
NCT02487225 · results posted 23 January 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02487225) looked at a medication called pentoxifylline compared to a placebo (a dummy treatment with no active ingredient) in people who were hospitalised. The trial enrolled 45 people in the pentoxifylline group and 38 in the placebo group — 83 participants in total. It was measuring changes in four substances found in the blood that are linked to inflammation: C-reactive protein (CRP), and three signalling proteins called TNF-alpha, IL-6, and IL-8. These were measured at the time of admission and again after one week. It...
-
NCT00782795 · results posted 11 December 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 people in total — 17 were given pioglitazone (a medication) and 8 were given a sugar pill (placebo). The trial was measuring how blood sugar regulation changed over time in participants who had received a kidney transplant and were being treated with a drug called tacrolimus, which can affect how the body handles sugar. Specifically, researchers tracked whether participants' blood sugar control was normal, impaired (somewhere in between normal and diabetes), or consistent with diabetes, at 24 weeks and again at 48...
-
NCT02116309 · results posted 1 November 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 960 people in total — 482 in one group and 478 in the other. All participants were undergoing a procedure called ERCP (a type of internal examination of the bile and pancreatic ducts) and were at risk of a complication called post-ERCP pancreatitis, which is inflammation of the pancreas that can occur after the procedure. One group received a rectal suppository of a medicine called indomethacin on its own, while the other group received the same suppository plus a spray of a medicine called epinephrine applied directl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01221311 · results posted 1 May 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 112 people in total — 57 in a group that received a fully covered metallic stent and 55 in a group that received a plastic stent. All participants completed the study period with no dropouts recorded. The trial was measuring what researchers called "early clinical success," which meant that when the stent or stents were removed (after up to 12 months of stent treatment), imaging showed the narrowing in the area being treated had resolved. Anyone who still had a narrowing after 12 months was counted as a clinical failu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00727740 · results posted 18 January 2017
According to the results reported on ClinicalTrials.gov, this trial involved 117 people in total — 56 who received indomethacin (an anti-inflammatory medicine) and 61 who received a placebo (an inactive treatment). The trial was looking at rates of a condition called post-ERCP pancreatitis (PEP) — that is, inflammation of the pancreas that can occur after a medical procedure called an ERCP (a procedure used to examine the digestive tract). Specifically, the trial measured whether there was a reduction in the percentage of participants who developed this complication. The reported data shows t...
See all 44 reported results for Pancreatitis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is being directed toward pancreatitis, and that level of investment has remained broadly steady from year to year. For patients, this suggests that pancreatitis is an established area of medical research interest, with consistent support to sustain ongoing scientific work. Steady funding often means researchers are cont...
See the full Pancreatitis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.